DIVERSA launches DIVTECH kits, a new solution for the cellular delivery of molecules, and continues its commercial expansion in Europe
After just three months since the incorporation of DIVERSA Technologies, the company has already struck some deals that will bolster its commercial activities within Europe
After just three months since the incorporation of DIVERSA Technologies, the company has already struck some deals that will bolster its commercial activities within Europe.
The first major milestone was the beginning of the commercialization of its technology in the European Union and the United Kingdom in February through tebu-bio, a French scientific distribution company. tebu-bio is a lab reagent distribution company based in Le Perray-en-Yvelines, a town Southwest of Paris. tebu-bio runs a wide variety of in vitro assays, in addition to providing specialty reagents. It has several branches throughout Europe, with more than 80.000 customers in the life sciences space.
DIVERSA’s ready-to-go kits (DIVTECH formulations) are designed for any lab in need of a drug delivery system. DIVERSA aims to become the partner of choice for drug delivery and pharmaceutical nanotechnology solutions. Currently the ready-to-go kits are designed for associating small molecules, peptides, and proteins. This year DIVERSA plans to launch more products for associating other types of molecules: mRNAs and antibodies.
The second line of activity is the partnering with biotech and pharma companies for co-development projects. DIVERSA is close to signing two agreements in the gene therapy and cosmetic areas. We hope to be able to announce these collaborations before the end of this month.
From an operational standpoint DIVERSA is seeking financing to keep up with the marketing and sales activities associated with the growth of the company. In this sense, the main objective is to close the seed funding round, which is currently being negotiated by the investors. DIVERSA is also applying for public funding. Specifically, funding aiming at internationalization of commercial activities. The company has two open applications: one with the ICEX NEXT program of the Spanish “Ministerio de Industria, Comercio y Turismo” and the other one with the EIT Health Bridgehead program.
DIVERSA’s project was granted in 2019 funds from the Ignicia program of the Galician Innovation Agency (GAIN) for the development of the business project (456.500 €) and this year, has received funds from the “Instituto Galego de Promoción Económica” (IGAPE), that will assist in the marketing efforts to make our brand and products known to our target audience: universities, research institutes, CROs, biotech and pharma companies.
Finally, from a human resources perspective, and given the increase in commercial activities and co-development projects, DIVERSA is currently hiring two new scientists for the lab in Santiago de Compostela. These positions will be filled during the current quarter.
We are still looking for one more position of a researcher with a strong background in nanotechnology. We will soon post an open position on the ASEBIO website. You can take part in our exciting company.